Albany Molecular Research (NASDAQ: AMRI) provides
contract services to pharmaceutical and biotechnology companies. The firm offers drug discovery, screening programs, libraries for screening and hit-to-lead programs, and analytical quantification of drugs and metabolites in biological samples. The company also conducts its own research, aiming to license its compounds to other firms for further development. Albany Molecular owns a patent for fexofenadine HCl, the key ingredient in Sanofi-Aventis' (NYSE: SNY) antihistamine Allegra.
The company pleased investors last week, when it reported Q2 EPS of 24 cents and revenues of $57.9 million. Analysts had been looking for ten cents and $51.8 million. The CEO noted that submission of a Canadian Clinical Trial Application by partner Bristol-Myers Squibb (NYSE: BMY) triggered a milestone payment to Albany that reflected well on the value of the company's strategic technology platform. Management also guided Q3 EPS to 8-10 cents (seven cent consensus) and FY08 EPS to 48-52 cents (38 cent consensus).
The AMRI price
popped on the news and then moved into a bullish "pennant" consolidation pattern. Stocks frequently exit pennants moving in the same direction they were traveling on entry. In this case, that would be to the upside.
The brokerage community recommends the issue with one "hold". Analysts see a 24% growth rate through the next year. The AMRI PEG ratio (1.56), Price to Book ratio (1.53) and EPS Growth rate (71.43%) compare favorably with industry, sector and S&P 500 averages. Institutional investors hold about 73% of the outstanding shares. Over the past 52 weeks, the stock has traded between $9.25 and $19.05. A stop-loss of $14.35 looks good here.
Larry Schutts is a contributing editor for Theflyonthewall.com and the Vice-President of Stockwinners.com. He does not hold positions in any of the stocks mentioned above.
Struggling Playboy outsources business ops
J. Crew earnings preview: A strong Q3 all buttoned up?
Twitter to make acquisitions, generate revenue in 2010
